AbbVie Q1 revenue up 12.4% to $15.0 billion; raises 2026 adjusted EPS outlook
AbbVie reported first-quarter 2026 net revenues of $15.002 billion, up 12.4% from a year earlier, and adjusted diluted EPS of $2.65, up 7.7%. GAAP diluted EPS fell 45.8% to $0.39 because of large charges, including a $2.387 billion pre-tax change in fair value of contingent consideration. The company raised its 2026 adjusted diluted EPS guidance to $14.08-$14.28 from $13.96-$14.16.
Key points
- Q1 2026 net revenues $15.002 billion, up 12.4% on a reported basis (10.3% operational)
- GAAP diluted EPS $0.39 vs. $0.72 a year earlier; adjusted diluted EPS $2.65 vs. $2.46
- Skyrizi net revenues $4.483 billion (up 30.9%); Rinvoq $2.119 billion (up 23.3%)
- 2026 adjusted diluted EPS guidance raised to $14.08-$14.28 from $13.96-$14.16, including a $0.41 per share acquired IPR&D and milestones charge in Q1
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 29, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.